

VANISHING UNDIAGNOSED GONOCOCCAL INFECTIONS IN AN URBAN AMERICAN COMMUNITY

Marcia M. Hobbs^a, Susan M. Rogers^b, Charles Turner^c, William C. Miller^a,
Kimberly D. Rich^a, John L. Schmitz^a and Elizabeth Eggleston^b

^aUniversity of North Carolina at Chapel Hill, USA

^bRTI, International, Washington, DC, USA

^cCity University of New York, USA



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL, USA



Objective: The Monitoring STIs Survey Program (MSSP) monitors trends in undiagnosed STIs among adolescents and young adults in an urban community in Maryland, US with historically high incidence of diagnosed STIs and high prevalence of undiagnosed STIs. We estimated the prevalence of undiagnosed gonococcal (GC) and chlamydial (CT) infections in 2006-2008 and compared these figures with data from a similar population survey conducted in the same community nearly a decade earlier (JAMA 2002 287:726).

Methods: From a probability sample of persons 15-35 years of age residing in community households with landline telephones, urine specimens were sent to the laboratory by mail with informed consent for STI testing. We used APTIMA Combo2 (Gen-Probe, Inc.) for GC/CT testing. Samples with initial positive results were retested and considered positive if both tests were positive. To assess effects of specimen collection and transport, negative urines were spiked with GC, mailed to the laboratory and tested. In the prior survey, urine collected at the household was kept chilled until laboratory testing by LCR (LCx, Abbott).

Results: Among 1712 urines tested, median volume was 60 mL (range, 10-100 mL). Samples were processed a median of 4 days after collection (range, 1-203 days). Under similar conditions, urines spiked with ≥ 250 cfu GC/mL (limit of detection for the assay) and mailed into the laboratory uniformly tested positive. Preliminary estimates show lower rates of undiagnosed GC and similar CT infection rates in the MSSP compared to the prior survey.

Conclusions: The diagnostic test had expected analytical sensitivity, even with specimens that exceeded recommended limits for urine volume and storage time. Alternate explanations for the observed decline in prevalence of untreated GC in this urban US community (e.g. variation in specimen collection and testing, decline in population prevalence of treated and untreated infection) are explored.

Table 1. Demographic and Social Characteristics of Survey Populations.

Characteristic	Weighted ^a % for survey period			
	'97-'98 (N = 579)	'06-'07 (N = 1248)	'07-'08 (N = 1033)	
Race	White	28.7	31.0	31.3
	Black	65.7	62.3	62.5
	Other	5.6	6.6	6.3
Gender	Women	52.0	52.1	52.2
	Men	48.0	47.9	47.8
Age	15-20	16.8	32.6	32.7
	21-25	23.9	23.3	23.0
	26-30	26.2	21.6	21.8
	31-35	33.2	22.5	22.5
Marital status	Never married	53.6	57.5	56.3
	Married	21.1	21.1	16.9
	Not married, living with partner	15.6	18.6	21.9
	Widowed, divorced, separated	9.6	2.9	5.0
Education	< 8 th grade	6.1	3.8	3.7
	Some high school	16.0	24.1	24.9
	High school graduate	36.6	26.8	28.0
	Trade/bus. sch./some college	27.8	24.0	22.2
	\geq College graduate	13.5	21.2	21.2

^aWeighted to reflect variations in probabilities of sample selection from population.

Table 2. Prevalence Estimates for STIs in Baltimore Population-Based Surveys 1997 – 2008.

Study Period ^b	Estimated ^a % Prevalence (SE or 95% CI) of infection with		
	<i>N. gonorrhoeae</i>	<i>C. trachomatis</i>	<i>T. vaginalis</i>
1997 – 1998 ^c	5.2 (SE, 1.4)	3.0 (SE, 0.8)	not done
2006 – 2007 ^d	0.1 (0.0, 0.7)	4.6 (2.7, 6.4)	6.3 (4.5, 8.1)
2007 – 2008 ^d	0.1 (0.0, 0.6)	3.3 (1.7, 4.9)	6.2 (4.2, 8.3)

^aWeighted to reflect variations in probabilities of sample selection from population.


^bFor comparison, local health department rates of diagnosed GC and CT were 2.6% and 2.1%, respectively, in 1998 and 1.6% and 3.4% in 2007.

^cPrevious study population included persons 18-35 years of age.¹

^dMSSP study population includes persons 15-35 years of age.

SPECIMEN COLLECTION, TRANSPORT AND TESTING METHODS

1997-1998 SURVEY



2006-2008 SURVEY

ACKNOWLEDGEMENTS. We thank Alice Stillson for processing MSSP urine specimens. This work was supported by the NC Sexually Transmitted Infections and Topical Microbicides Cooperative Research Center grant (U19-AI031496) funded by the US National Institute of Allergy and Infectious Diseases and by a grant (R01-HD047163) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development.

SPECIMEN VALIDATION & QUALITY CONTROL FOR APTIMA TESTING

Figure 1. APTIMA Combo 2 (AC2) detects *N. gonorrhoeae* (GC) below the published analytical sensitivity in urine spiked with whole GC and processed within 24h. However, when the same samples were mailed into the laboratory and processed 10 days after collection, specimens containing ≤ 10 cfu/mL (red circles) were negative. Data plotted are mean RLU $\times 1000 \pm$ sem from 6 samples at each concentration processed according to Gen-Probe instructions. $R^2 = 0.999$ for the nonlinear regression graph with data from freshly prepared urine specimens.




Table 4. APTIMA repeat testing results.

Test Result	Number of specimens retested for					
	GC		CT		TV	
Pos	2	2	47	47	96	97
Neg	123	124	78	79	33	45
Eqv	1	0	1	0	13	NA

Repeat testing was performed on all specimens with initial positive or equivocal results for GC, CT or TV. Pos, positive; Neg, negative; Eqv, equivocal; NA, not applicable. For TV testing, initial results between 10,000 and 30,000 RLU were considered equivocal. Initially equivocal specimens with repeat results $\geq 10,000$ RLU were defined as TV positive; those with repeat results $< 10,000$ were defined as TV negative.

Self-collected vaginal swabs from women. During the 3rd year of the MSSP, we are obtaining vaginal swabs in addition to urine from female respondents. To date, testing from 41 pairs of specimens suggests that urine is 60% sensitive for APTIMA STI testing compared to vaginal swabs. **However, no additional cases of undiagnosed gonorrhea have been detected in vaginal swabs.**

REFERENCES

- Turner CF, Rogers SM, Miller HG, Miller WC, *et al.*, 2002 JAMA 287:726-733.
- Isbey SF, Alcorn TM, Davis RH, *et al.* 1997 Genitourin Med. 73:378-382.

Table 3. MSSP urine specimen limitations.

Characteristic	APTIMA STI Results ^a		P value ^b
	Positive (N = 136)	Negative (N = 1361)	
Volume (mL) median	60	60	0.392
range	10, 100	10, 100	
% over 30 mL	91.9	94.2	0.375
% reporting < 1h since previous urination	14.0	9.8	0.162
Interval between collection and processing (days) median	5	4	0.022
range	1, 203	1, 70	

^aPositive = positive for GC, CT or TV; Negative = negative for GC, CT and TV.

^bZ-test for proportions; Rank Sum Test for specimens volume and time to processing.

CONCLUSIONS

- The majority of specimens in the MSSP exceed Gen-Probe limitations for urine volume, time since previous void and time to processing. **Nevertheless APTIMA Combo 2 reliably detects ≥ 250 gonococci per mL urine under the conditions of this study.**
- Infections with fewer organisms would not be identified under these conditions. Organism burdens from men with gonococcal urethritis are on the order of $\sim 10^3$ cfu/mL urine², well above the limit of detection of APTIMA Combo 2. **The concentration of gonococci in urine of asymptotically infected individuals is not known.**
- Despite similar prevalence estimates for unrecognized chlamydial infection, **undiagnosed gonorrhea is currently rare in Baltimore, MD and prevalence is over 98% lower than reported estimates for 1997-1998.** Reported cases of gonorrhea have decreased by only 39% over the same period, suggesting that the earlier study may have overestimated the prevalence of unrecognized gonococcal infection.